Xenon Pharmaceuticals Inc.

The biopharmaceutical company specializes in discovering, clinically developing, and commercializing therapeutics aimed at treating neurological and psychiatric conditions. Its primary focus is on advancing ion channel modulators, featuring its lead investigational candidate, azetukalner, a Kv7 potassium channel opener evaluated in late-stage clinical trials for focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. Additional early-stage programs target sodium and potassium channels for indications including pain and Dravet syndrome, alongside partnered research initiatives for epilepsy. The organization designs its therapies for patients suffering from difficult-to-manage central nervous system disorders.

The company's clinical research spans multinational sites across several countries, with trials enrolling patients in regions including the United States and Japan. In addition, its business activities involve strategic cross-border collaborations and licensing agreements with global pharmaceutical partners to advance select candidates worldwide. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Xenon Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 370 employees, including 358 full-time and part-time regular employees, of which 183 are located in Canada and 175 are located in the U.S.”